ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASSEMBLY BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.16+0.07 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $380.09M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-16.8%+65.1 pts over 5 years
Net margin
-8.5%+70.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +153.5% | – | -1.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -44.6% | -24.2% | -5.1% | |
| Return on assets | -38.2% | -19.9% | -3.2% | |
| Current ratio | 7.52 | 9.19 | 5.22 | |
| Capex to revenue | – | 0.6% | 0.1% | |
| Diluted shares | 1M | 3M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Assembly Biosciences generated $292.81M from operations and spent $3.55M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$292.81M
Used
$3.55M
Capital expenditure$3.55M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-8.5%
×Asset turnover0.38×
×Equity multiplier1.57×
=Return on equity, FY2025-5.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -8.5% | 0.38× | 1.57× | -5.1% |
| FY2024 | -140.9% | 0.22× | 3.44× | -107.9% |
| FY2023 | -854.8% | 0.06× | 1.93× | -98.9% |
| FY2021 | -2076.4% | 0.03× | 1.16× | -63.4% |
| FY2020 | -78.6% | 0.25× | 1.21× | -24.2% |
| FY2019 | -611.6% | 0.05× | 1.26× | -40.4% |
| FY2018 | -613.0% | 0.07× | 1.35× | -56.1% |
| FY2017 | -474.7% | 0.07× | 1.39× | -44.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$6.12M
- Cash generatingOperating cash flow above zero-$41.09M
- Return on assets improvedROA up on the prior year-29.4% → -5.1%
- Earnings backed by cashOperating cash flow above net income-$41.09M vs -$6.12M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.42 → 5.22
- No dilutionShare count did not rise6M → 11M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.21 → 0.61